Biosyn is a specialty pharmaceutical company developing novel, topical-delivery drugs for the treatment and prevention of infectious disease in areas of critical medical need. The Company has built a robust pipeline based upon four technology platforms addressing major anti-infective markets where the use of topical delivery offers significant advantages over systemic therapy.
In the area of HIV and STD prevention, Biosyn has become a leader in the development of microbicides, intra-vaginal gels to prevent or reduce transmission of sexually transmitted diseases (STDs). The Company’s lead compound, Savvy®, has recently completed Phase I/II safety and efficacy studies successfully and is positioned to enter Phase II/III clinical trials for the prevention of chlamydia, herpes simplex virus (HSV), HIV and other sexually transmitted diseases (STDs). A second microbicide candidate, UC781, is in late preclinical development and a third microbicide candidate is in early preclinical development. In addition to its microbicide portfolio, the Company has product development ongoing in several areas including oral complications of immuno-suppression, skin and soft tissue infections, and ophthalmic infections.
| Contact Details: |
| 1800 Byberry Road, Building 13 |
| Huntingdon Valley |
| PA |
| 19006 |
| United States of America |
| Tel: | 215.914.0900 |
| Fax: | 215.914.0914 |
| Email: | khl@biosyn-inc.com. |
| WWW: | www.biosyn-inc.com/
|
|
Loading...
|
Recent Publications by BioSyn Incorporated: |  |
A peptide hydroxamate library for enrichment of metalloproteinases: towards an affinity-based metalloproteinase profiling protocol.
A compound library of 96 enantiopure N-terminal succinyl hydroxamate... | 4th July, 2008
| Department of Bio-organic Synthesis (BioSyn), Leiden University, PO Box
| Org Biomol Chem. 2008 Apr 7;6(7):1244-50. Epub 2008 Feb 22.
DOI Direct Link |
In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials.
The development of vaginal microbicides for the prevention of sexual... | 24th January, 2006
| Biosyn, Inc., Huntingdon Valley, PA 19006, USA.
| AIDS Res Hum Retroviruses. 2005 Oct;21(10):845-53.
DOI Direct Link |
Expression, purification, and characterization of recombinant cyanovirin-N for vaginal anti-HIV microbicide development.
Cyanovirin-N (CV-N) is a prokaryotic protein under development as a... | 27th May, 2005
| Biosyn, Incorporated, 1800 Byberry Road, Building 13, Huntingdon Valley,
| Protein Expr Purif. 2005 Feb;39(2):229-36.
DOI Direct Link |
Microbicides--evaluating multiple formulations of C31G.
Despite a significant worldwide need for effective microbicides to reduce... | 2nd May, 2003
| Biosyn, Inc, 1800 Byberry Road, Building 13, Huntingdon Valley, PA 19006,
| Contraception. 2002 Nov;66(5):365-8.
|
Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 269 times since April 2007, the link to the organisation's website has been followed 43 times
Recent Search Terms used to find this page: biosyn huntingdon valley pa | biosyn huntingdon valley pa | f | biosyn leiden | BIOSYN HUNTINGDON VALLEY PA | t | BIOSYN INCORPORATED | BIOSYN INCORPORATED | biosyn incorporated pa | biosyn incorporated | .
Search for more companies in Huntingdon Valley
Search for more companies in PA
This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for
BioSyn Incorporated
